Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, provides an overview of the evolving treatment landscape in Fabry disease.
With no treatment options for Fabry disease 20 years ago, there are now 2 treatments approved and several new options being investigated for use, said Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center.
Transcript
What are some future considerations regarding management of Fabry disease?
Fabry disease is a changing field constantly, and right now most of the patients who are being treated have very little enzyme production from the copy of the gene that's abnormal. So, in men, they only have 1 copy, and in women, they have 2 copies, but the cells with X inactivation, the cells that have the abnormal copy of the gene, usually don't make any and there's, for reasons we don't understand, not cross correction between the cells.
We need to pay attention to the treatment options. We've gone from no treatment 20 years ago to now we have 2 treatments, and there are probably at least 10 groups studying newer options to improve the outcome for people with Fabry disease.
So, scientifically, it's an exciting time. Probably in the next 5 to 10 years, we will have some treatments that are less of a burden on the patients. And I think that it behooves the medical care providers and the patients with Fabry disease to keep an eye on this evolution so that we can take advantage of what we're learning as the science advances.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More